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Abstract
Background:  Despite important improvements in available prevention and treatment,
cardiovascular diseases (CVD) remain an important cause of morbidity and mortality. Not all high-
risk patients and patients with CVD have healthy lifestyles and receive the best possible healthcare.
Internationally comparative data are needed to compare cardiovascular risk management in
different countries, and to examine the impact of improvement programs and others factors.
Objectives: This study aims to provide internationally comparative data on cardiovascular risk
management provided in primary care and on health-related lifestyles of patients in Europe. The
study will also explore the views of doctors and patients on innovative preventive services for
CVDs.
Design and methods: An observational cross-sectional study is planned. In 10 European
countries, stratified samples of 36 practices per country will be recruited. In each practice, three
samples of 15 patients each will be sampled: patients with coronary heart disease, patients at high
risk for CVD, and healthy adult patients. The quality of cardiovascular risk management has been
specified in terms of 44 performance indicators that resulted from an international Delphi-
procedure with general practitioners. Most indicators are based on medical records, and some on
a structured interview with a contact person of the practice. Lifestyle (smoking, physical exercise,
diet) will be measured with previously validated questionnaires that are completed by patients.
Additional measures include practice characteristics and exposure to programs to improve
cardiovascular care.
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Background
Cardiovascular diseases (CVD) have a major impact on
the mortality and quality of life of human populations
across the world, despite improvements in lifestyle and
innovations in the prevention and treatment of CVD in
previous decades [1]. Cardiovascular risk management
includes the clinical management of established CVD,
prevention of CVD in patients at high risk for developing
CVD, and improvement of health-related lifestyles in the
population [2]. Though numbers of deaths from coronary
heart disease (CHD) in developed countries have declined
[3] and cardiovascular care may have improved in recent
years [4], many eligible individuals currently still do not
receive the best available treatment and prevention for
CVD [5]. A better insight into cardiovascular risk manage-
ment in primary care and health-related lifestyles of
patients could help to develop effective programs for
improving current practice.
Data on current cardiovascular risk management and
patients' lifestyles are needed, both to identify perform-
ance gaps and set specific targets for improvement, and to
identify underlying factors and tailor interventions to rel-
evant barriers for change. We do not have specific hypoth-
eses on the quality of cardiovascular risk management or
patients' lifestyles, except that we expect much variation
across patients and practices within each of the countries.
Inadequate delivery of cardiovascular risk management
may be related to various factors. For instance, it may be
related to inadequate perception of cardiovascular risk by
physicians [4], as well as to concerns about the efficiency
and ethical implications of providing cardiovascular pre-
vention to individuals at low risk for developing CVD [6].
The clinical benefits and efficiency of primary and second-
ary prevention are continued topic of scientific debate [7].
Alternatively, it may be related to organizational and
financial barriers in practice organizations for providing
cardiovascular risk management. For instance, organiza-
tional characteristics of general practices, such as size of
scale and teamwork, proved to be associated with provid-
ing cardiovascular risk management [8].
While data on cardiovascular risk management are availa-
ble in a number of countries, our planned study aims at
providing internationally comparative data. Such data
have a potential advantages compared to national data.
Trends and associations identified in international data-
sets may be more robust for the confounding influence of
national healthcare systems and national cultures. For
instance, studies in different European studies showed
across these countries that patient evaluations of accessi-
bility were most positive in small general practices [9],
and that physician workload per 1,000 patients was con-
sistently lower in larger practices [10]. The consistency of
these findings makes it more likely that the associations
were not confounded by characteristics of a specific
healthcare system or national culture. Furthermore, inter-
national comparison of performance between different
countries can stimulate stakeholders for improvement,
although country differences can often be attributed to
many other factors than those of interest.
Our focus is on primary care, because a substantial part of
prevention and chronic care for CVD is delivered in this
sector. Many countries have large-scale programs to
improve cardiovascular risk management in primary care,
such as disease management programs in Germany [11],
indicator-based incentive contracts in the United King-
dom [3], and practice support in outreach visits in The
Netherlands [12]. Interestingly, these programs tend to
focus either on risk management in patients with estab-
lished CVD in some countries, and on lifestyle education
for the population in other countries [13]. An important
question is what impact exposure of a practice to these
programs has on the quality of cardiovascular risk man-
agement. Internationally comparative data can enable a
comparison of programs across countries.
Aims and objectives
This study protocol concerns an international study of car-
diovascular risk management in primary care in Europe.
Its overall aim is to provide insight into the current serv-
ices delivered in primary care to prevent CVD, with the
aim to inform and support primary care practices as well
as national health policies and decision makers in this
domain. Appendix 1 provides definitions of key concepts
in this study protocol.
Key objectives are:
1. To describe the quality of cardiovascular risk manage-
ment services provided to patients with established CHD
and to patients with high risk for developing CVD in pri-
mary care using performance indicators, and to compare
countries in these domains.
2. To describe specific aspects of health-related lifestyle
(smoking, physical exercise, diet) in high risk patients and
in healthy patients in general practice across Europe.
3. To determine the association between exposure of a
practice to quality improvement programs and the quality
of cardiovascular risk management and patients' lifestyles.
4. To identify associations of the quality of cardiovascular
risk management provided and characteristics of patients,
health professionals, primary care practices, and countries
with different health care systems.Implementation Science 2009, 4:3 http://www.implementationscience.com/content/4/1/3
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5. To describe the experiences and views of general practi-
tioners (GPs) and healthy adults on what innovative serv-
ices a general practice could provide regarding primary
prevention of CVD.
Hypotheses
While the study is mainly descriptive and explorative
(aimed at generating hypotheses), we tentatively formu-
lated the following hypotheses:
Hypothesis one: The quality of cardiovascular risk man-
agement shows variation across countries, general prac-
tices, and patients (differences of 15% or more on
performance indicators).
Hypothesis two: Better cardiovascular risk management is
associated with the following practice characteristics:
1. More structured practice management, including
implementation of information technology, organisation
of chronic care and prevention, and structured quality
improvement.
2. Involvement of more health professions in the practice
in providing cardiovascular risk management and in pre-
ventive activities in general.
3. Larger practice size, because of size of scale advantages.
4. More exposure to and engagement of the practice in car-
diovascular quality improvement projects and continuing
education by health professionals on cardiovascular care.
Hypothesis three: At a country level, better quality of car-
diovascular risk management in patients with CHD is
associated with:
1. A stronger primary care system in the country
2. Nationwide programs to improve cardiovascular risk
management in general practice
Design and methods
The study has a cross-sectional observational design. It is
internationally comparative (focused on description and
comparison of countries) and explorative (focused on fac-
tors in patients, professionals and practices associated
with outcomes). Ethical approval for the study will be
sought in each of the participating countries, according to
national laws and regulations.
Study populations
The study includes patients, health professionals, and
general practices in different countries.
Countries
We include 10 countries: Austria, Belgium, England, Fin-
land, France, Germany, Netherlands, Slovenia, Spain, and
Switzerland. This is a comprehensive sample of countries
in North, West, South and Central Europe. Although all
these countries have primary care practices, there is sub-
stantial heterogeneity regarding the position of primary
care in the healthcare system. For instance, primary care
physicians coordinate access to specialized medical care
only in some countries, while medical specialists can be
consulted directly in other countries.
Practices
Stratified random sampling of 36 practices per country is
planned. This sample size was chosen because it is feasible
in the context and budget of this project, while experience
showed that it has been large enough to give robust results
and can be considered reasonably representative for a
country. A general practice is the smallest organisational
unit, in which primary care physicians are based in their
daily work to provide care to patients. The practice may be
part of a larger organisational network, such as a multidis-
ciplinary health centre or primary care trust (for instance
to share patient lists, financial risk, legal accountability,
support staff, etc.). This wider organisational context is
not considered in the sampling in this project.
We aim to select representative samples of practices per
country. Random sampling would be the best method,
but the sample is not likely to be representative if only a
small minority of randomly sampled practices accept the
invitation to participate in the study. It was considered to
be important that the sample of practices roughly repre-
sents the national situation as closely as possible, both for
the generalisability of our findings and for drawing policy
implications. Country partners are instructed to avoid
recruiting only a special type of practice, such as training
practices, academic practices, or practices in a special local
network.
We aim for a stratified random sample, using two factors
internationally for stratification: practice size and urbani-
sation (See Table 1). The assumption is that these factors
are prognostic for our main measures of cardiovascular
Table 1: International stratification scheme.
Practice size Population density
Rural/town Urban
Small A C
Large B DImplementation Science 2009, 4:3 http://www.implementationscience.com/content/4/1/3
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risk management – although strong research evidence to
support this claim is lacking. The definition is as follows:
Practice size
Small practice size is defined as up to two full-time equiv-
alent (FTE) primary care physician, while large practices
have more than two FTE primary care physicians (regard-
less of their type of contract and reimbursement; but
excluding trainees and nurse practitioners)
Urbanisation
Urban is defined as more than 100,000 inhabitants; rural
or town is defined as less than 100,000 inhabitants (con-
sidering the geographical location of the practice,
although the patients may come from other areas).
The actual numbers in the cells (Table 1A, B, C, and 1D)
are to reflect each county's national situation as much as
possible, even if this means that in some countries some
cells have few or no practices. For example, if a country
has no large practices, cells B and D would be empty in
that country. Country project partners are instructed to
develop additional criteria for stratifying the sample in
their country according to practice size and urbanization,
particularly if some cells in the international stratificiation
table were empty. For example, if most practices are larger
than two FTE GPs, two strata within the larger practices
may be defined (e.g., up to four FTE GPs versus five FTE
GPs or more). Project partners are asked to provide infor-
mation on the planned and actual stratification table for
their country.
Within each of the strata, each country partner is asked to
sample randomly from a regional or national list of prac-
tices. In other words, if a practice declines, a similarly sam-
pled practice from the same stratum will be approached.
For logistical reasons it is acceptable to sample in one or a
few geographical areas in a country. The degree to which
these regions represent the country as a whole will be
described qualitatively in terms of health system and pop-
ulation health.
Health professionals
The study considers all staff physically working in each
general practice, including physicians, nurses (nurse prac-
titioners, practice nurses, specialised nurses, psychiatric
nurses etc.), practice assistants (whether or not with clini-
cal tasks), allied health professionals (physiotherapists
etc.), psychologists, midwives, physician assistants,
administrative people, and managers. The staff may be
employed by the practice or by another organisation (e.g.,
nurses in the practice, who are employed by mental health
organisation). The study excludes staff working in the
same health centre, or other larger organization, but based
in a different practice.
Patients
The study is focused on three patient samples, which will
be identified in each of the participating practices:
Patients with established CHD. This includes myocardial
infarction, angina pectoris, or vascular surgery (diagnoses
based on medical records at the general practice). Patients
with established diabetes are excluded to enhance the
homogeneity of the study population.
Patients with high risk for developing CVD. This includes
meeting one of the following criteria: 10% CVD mortality
risk or 20% CVD morbidity risk in 10 years, ideally based
on an individual risk assessment using validated CVD risk
tables. If this is not available, we defined a proxy measure:
presence of three out of the following four risk factors:
hypertension, hypercholesterolemia, smoking, men over
60 years (cut-off points as defined nationally). Patients
with established diabetes or established CVD are excluded
from this group.
Patients aged 18 to 45 years (unselected), registered or
regular visitors in the practice. The underlying argument
for focusing on this age group is that we assume that
health behaviors at younger age tend to be continued at
later age.
Exclusion criteria for all patient samples are: terminal ill-
ness, cognitive impairment, psychiatric illness, and poor
language skills.
Procedures
For the first two patient samples (CHD patients and high
risk patients) we plan to collect data from medical records
and from patient questionnaires. Depending on the
national context and regulations, different procedures
may be used. In countries where informed consent is
requested, 30 patients will be sent the questionnaire with
an informed consent form for abstracting medical record
data, expecting at least 50% informed consent forms will
be returned. Then, data are abstracted from those patients'
medical records. If no informed consent is required, a
sample of 15 patients will be identified for data-extraction
from their medical records. A larger sample of patients (n
= 30), including these 15 patients, will be identified and
sent questionnaires. These procedures were tested in a
pilot studies in some general practices in each of the coun-
tries, and the results were discussed in a plenary interna-
tional meeting of all researchers in order to standardize
the sampling procedures as much as possible.
For the third sample, adults 18 to 45 years, we will take a
random sample of a list of patients registered at the prac-
tice. In countries where there is no patient registration,
alternative methods will be based on a sample of patientsImplementation Science 2009, 4:3 http://www.implementationscience.com/content/4/1/3
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taken from a list; e.g., by taking every second or third
patient until 40 patients are selected.
Accuracy of figures
The accuracy of the figures is focused on the confidence
interval associated with mean values rather than on differ-
ences between countries, practices, or subgroups. We will
aim for high accuracy of the figures per country, and will
use n = 36 practices per country as the maximum feasible
number. We estimate an average score of 65% in a specific
country, e.g., 65% of patients receive care according to a
specific indicator (dichotomous outcome) or 65% of the
maximum score on a continuous outcome (e.g., a five-
point answering scale). A design effect based on ICC =
0.05 is assumed. Power = 0.80 and alpha = 0.05. We will
aim for 95% CI interval of 60 to 70%, so we will need 493
patients per country (n = 14 per practice). For each indica-
tor and measure data will be collected from 15 patients
(from records or questionnaires) per practice. The actual
number of patients approached depends on the procedure
and the expected response rate, and may therefore vary
across countries.
Measures
The following measurement methods will be used: medi-
cal record audit, patient questionnaires, and a question-
naire and an interview guide for a contact person in each
practice. Specific measures include (see also Table 2.):
1. The EPA Cardio instrument, which is a set of indicators
and related measures. The EPA Cardio instrument was
based on a modified Delphi procedure to identify relevant
indicators [14]. A total of 101 GPs from nine countries
(80% of those invited) was involved in both rounds of
this procedure. These countries were included again in
this observational study, except for Spain which was
added later. From an initial list of 650 indicators, 202
indicators were derived, from which 44 were rated valid
Table 2: Measurement domains and data collection methods
Data-abstraction from 
sampled medical 
records
Interview and 
questionnaire for 
contact persons in the 
practice
Survey in CHD 
patients
Survey in high risk 
patients
Survey in healthy 
patients
1. Clinical and 
organisational 
performance in 
cardiovascular 
prevention 
(= EPA Cardio 
instrument)
XX
2. Engagement of the 
practice in quality 
improvement projects
X
3 Practice 
characteristics, 
including EPA 
dimensions
X
4a Patient 
demographics and 
chronic diseases
XXX
4b PACIC X
4c. EQ-5D X X
4d EUROPEP X X X
4e Lifestyle: smoking, 
physical exercise, diet
XX
5 Views on primary 
primary prevention in 
general practice
XXImplementation Science 2009, 4:3 http://www.implementationscience.com/content/4/1/3
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(22%). Only indicators that scored high on necessity and
feasibility in each of the country panels were included.
These indicators covered lifestyle (8), clinical perform-
ance (27), and organisational aspects (9), and are incor-
porated in the following instruments: abstraction tool for
a medical record audit in CHD patients; abstraction tool
for a medical record audit in high risk patients; and an
interview guide for an interview with the GP.
2. Health related lifestyles. In high risk and healthy
patients, we will use questionnaires for specific aspects of
lifestyle, including physical exercise (RAPA, 9 items) [15],
diet (reduced REAP-S, 12 items) [16], and smoking (MID-
SIZED Model, 8 items) [17].
3. Other measures on patients. In all patients (CHD, high
risk and healthy), the questionnaires include items on
demographic characteristics, healthcare use, chronic dis-
eases, and patient experience with general practice
(Europep new version, 23 items) [18]. In CHD and high
risk patients, we added the EQ-5D (5 items + VAS scale)
[19] and report on adherence to medication, if relevant (4
items) [20]. In CHD patients, we added the Patient Assess-
ment of Chronic Illness Care (PACIC, 26 items) [21]
4. Practice engagement in quality improvement programs
and education. The following items are measured in the
interview with the GP or practice manager and in the prac-
tice questionnaire: practice engagement in cardiovascular
quality improvement projects; practice engagement in
public health projects concerning cardiovascular risk;
practice engagement in other projects concerning cardio-
vascular risk management (structured lists of projects are
used that are adapted to the national situation). A struc-
tured questionnaire for the GP/practice manager includes:
questions on exposure to education and campaigns by
nurses and GPs (five items); the average number of hours
of continuing education on CVD and diabetes spent by
health professionals in the practice in the previous two
years (five items).
5. Other measures on practices. A written questionnaire is
used to measure several practice characteristics: informa-
tion process technology (EPA dimension, 11 items);
organisation of chronic care and prevention (EPA dimen-
sion, 19 items); quality improvement (EPA dimension,
eight items); practice staff tasks in cardiovascular care (five
items for five types of staff); and practice size, in terms of
listed patients and/or yearly attending patients. [22]
6. Innovative preventive services. A questionnaire has
been drafted to explore the views of GPs and patients
regarding what general practice could contribute to pri-
mary prevention of CVD. These questions are future-ori-
ented, which implies that many doctors and patients are
expected to have little or no experience with specific pre-
ventive activities. Also, the research evidence for effective-
ness of the primary preventive services may be lacking or
inconsistent.
All measures were translated systematically, using a for-
ward and backward translation procedure and a testing
phase with interviews. The final instruments were tested
and adapted in a pilot project. In this project, the proto-
types were tested in five countries in two practices each.
This experience led to some minor adjustments in the
audit forms and questionnaires. The measurements on
primary prevention and the patient questionnaire for the
18 to 45 year age group was added after discussion to
broaden the scope of the study: not just patients with
established CVD (especially CHD) and patients at high
risk, but also the generally healthy 18 to 45 year age
group.
Data-processing and data-analysis
In each of the participating countries, data will be entered
into a database (Excel, SPSS, or other data management
program). Some participants will make use of automated
data-entry systems and other participants will use double
entry of data to reduce errors. All frequency distributions
will be checked for errors and the number of missing val-
ues will be noted. We will attempt to identify signs of
responder fatigue, e.g., a series of questions that receive
the same score. Also, we will examine the case mix of dif-
ferent practices in order to identify possible selection bias,
caused by the sampling procedures.
Then, the findings will be described for each measure sep-
arately on a country-by-country basis. Appropriate sum-
mary measures will be used, such as mean and median
values. The accuracy of the figures will be expressed in
terms of 95% confidence intervals, taking into account
that the data are nested at two levels: patients in practices,
and practices in countries. A correction will be made for
the nested data structure to avoid inappropriately inflated
accuracy. We will examine qualitatively how the results of
each country are related to the assessment of the quality
indicators by the GP panel in that country.
Further statistical analysis of comparisons between sub-
groups in the project (defined by patients, practices, or
countries) will take this nested data structure into
account. Therefore, random coefficient regression models
will be applied (linear or logistic, as appropriate). To
reduce the possibility of chance capitalization, we will use
p < 0.01 to indicate significance in explorative analyses
and the conventional p < 0.05 in hypothesis-driven anal-
yses.Implementation Science 2009, 4:3 http://www.implementationscience.com/content/4/1/3
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Time frame
The EPA Cardio project is planned from November 2005
to June 2009. The study described in this protocol is
planned for March 2008 to April 2009.
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Appendix 1 – Definitions
'Cardiovascular diseases' refer in this project to diseases
due to atheroscleroris, such as angina pectoris, myocardial
infarction, and stroke (CVA). Diabetes mellitus is also
considered CVD by some experts, but this project does not
focus on diabetes (except that it is recorded as co-morbid-
ity).
'Cardiovascular risk factors' include age, gender, lifestyle
factors (smoking, poor diet, overweight, physical inactiv-
ity, problematic use of alcohol), and clinical factors (dia-
betes, hypertension and serum cholesterol). The specific
definitions of these factors, and the cut-off levels for high
risk, vary across clinical guidelines. For instance, various
blood pressure levels have been used to define hyperten-
sion. Increasingly, policy and practice focus on a patient's
global risk rather than individual risk factors
'Cardiovascular risk management' is used broadly and
includes the following target groups: the total population,
particularly individuals with unhealthy life-styles; indi-
viduals who have high risk for CVD, which is defined in
different ways and may be based on one or more risk fac-
tors; and patients who have established CVD.
Acknowledgements
Bertelsmann Foundation (Gütersloh, Germany) initiatied and co-ordinated 
the EPA Cardio project, in collaboration with IQ Healthcare of the Rad-
boud University Nijmegen (Nijmegen, The Netherlands). Bertelsmann 
Foundation also supported the project financially (without restrictions on 
the scientific work) and each of the project participants invested additional 
resources in the project. The following individuals were part of the EPA 
Cardio group, besides the authors of this study protocol: Ester Cornelis 
(Belgium), Eva Frigola (Spain), Glyn Elwyn (UK), Reinhold Glehr (Austria), 
Margalit Goldfracht (Israel), Hector Falcoff (France), Lilian Michlig (Switzer-
land), Esko Kumpusalo (Finland), Janko Kersnik (Slovenia), Kati Kettunen 
(Finland), Beat Künzi (Switzerland), Solene Martin (France), Davorina Petek 
(Slovenia), Ingrid Pichler (Austria), Martin Roland (UK), Marianne Samuel-
son (France), Veerle van der Stighelen (Belgium), Luc Seuntjes (Belgium), 
Joachim Szcescenyi (Germany), Trudy van der Weijden (Netherlands).
References
1. Weisfeldt ML, Zieman SJ: Advances in the prevention and treat-
ment of cardiovascular disease.  Health Aff 2007, 26:25-37.
2. Fourth Joint Task Force of the European Society of Cardiology and
Other Societies: European guidelines on cardiovascular dis-
ease prevention in clinical practice: executive summary.  Eur
Heart J 2007, 28:2375-2414.
3. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE,
Giles WH, Capewell S: Explaining the decrease in U.S. deaths
from coronary disease, 1980 – 2000.  N Engl J Med 2007,
356:2388-98.
4. Campbell SM, Roland MO, Middleton E, Reeves M: Improvements
in quality of clinical care in English general practice 1998 –
2003: longitudinal observational study.  BMJ 2005,
331:1097-1098.
5. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsch BW,
Fabunmi RP, Kwan J, Mills T, Simpson SL: National study of physi-
cian awareness and adherence to cardiovascular disease pre-
vention guidelines.  Circulation 2005, 111:499-510.
6. Getz L, Kirkengen AL, Hetlevik I, Romunstad S, Sigurdsson JA: Ethi-
cal dilemmas arising from implementation of the European
guidelines on cardiovascular disease prevention in clinical
practice.  Scan J Prim Health Care 2004, 22:202-208.
7. Unal B, Critchley A, Capewell S: Modeling the decline in coro-
nary heart disease deaths in England and Wales, 1981–2000:
comparing contributions from primary and secondary pre-
vention and secondary prevention.  BMJ 2005, 331:614.
8. Lobo CM, Frijling BD, Hulscher MEJL, Bernsen RMD, Braspenning JC,
Grol RPTM, Prins A, Wouden JC Van der: Organisational deter-
minants of cardiovascular prevention in general practice.
Scan J Prim Health Care 2003, 21:99-105.
9. Wensing M, Hermsen J, Grol R, Szecsenyi J: Patient evaluations of
accessibility and co-ordination in general practice in Europe.
Health Expect 2008.
10. Wensing M, Hombergh P Van den, Van Doremalen, Grol R, Szecsenyi
J: General practitioners' workload associated with practice
size rather than chronic care organization.  Health Policy 2008,
89(1):124-129.
11. Beyer M, Gensichen J, Szecsenyi J, Wensing M, Gerlach FM: Wirk-
samkeit von Disease-Management-Programmen in Deutsch-
land – Probleme der medizinischen Evaluationsforschung
anhand eines Studienprotokolls.  Zeitschrift für Ärtztliche Fortbil-
dung und Qualität in Gesundheitswesen 2006, 100:355-364.
12. Hulscher ME, Van Drenth BB, Wouden JC Van der, Mokkink HG, Van
Weel C, Grol R: Changing preventive practice: a controlled
trial on the effects of outreach visits to organize prevention
of cardiovascular diseas.  Qual Health Care 1997, 6:19-24.
13. Van Lieshout J, Wensing M, Campbell S, Grol R: Primary care
strength linked to prevention programs for cardiovascular
disease.  Unpublished paper 2008.
14. Campbell S, Ludt S, Van Lieshout J, Boffin N, Wensing M, Petek D,
Grol R, Roland M: Quality indicators for the prevention and
management of cardiovascular disease in primary care in
nine European countries.  Eur J Cardiovasc Prev Rehab 2008,
15(5):509-515.
15. Topolski TD, LoGerfo J, Patrick DL, Williams B, Walwick J, Patrich
MB: The rapid assessment of physical activity (RAPA) among
older adults.  Prev Chronic Dis 2006, 3:A118.
16. Segal-Isaacson CJ, Wylie-Rosett J, Gans KM: Validation of a short
dietary assessment questionnaire: the rapid eating and activ-
ity assessment for participants short version (REAP-S).  The
Diabetes Educator 2004, 30:774-781.
17. Behavior Change Consortium, mid-sized model smoking
measure mid-size model   [http://www1.od.nih.gov/behavior
change]
18. Grol R, Wensing M, Mainz J, Jung HP, Ferreira P, Hearnshaw H, Hjort-
dahl P, Olesen F, Reis S, Ribacke M, Szecsenyi J: Patients in Europe
evaluate general practice care: an international comparison.
Br J Gen Pract 2000, 50:882-887.
19. EQ-5D, an instrument to describe and value health   [http://
www.euroqol.org]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Implementation Science 2009, 4:3 http://www.implementationscience.com/content/4/1/3
Page 8 of 8
(page number not for citation purposes)
20. Moriskey DE, Green LW, Levine DM: Concurrent and predictive
validity of a self-reported measure of medication adherence.
Med Care 1986, 24:67-74.
21. Glasgow RE, Nelson CC, Whitesides H, King DK: Use of the
Patient Assessment of Chronic Illness Care (PACIC) with
diabetes patients.  Diab Care 2005, 28:2655-61.
22. Engels Y, Dautzenberg M, Campbell S, Broge B, Boffin N, Marshall M,
Elwyn G, Vodopivec-Jamsek V, Gerlach FM, Samuelson M, Grol R:
Testing a European set of indicators for the evaluation of the
management of primary care practices.  Fam Pract 2006,
23:137-147.